ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / LIMN / news
CRIS (27) PMCB (34) BTTC (38) CELZ (20) ⌘ Pro Terminal →

Why LIMN Stock dropped -10.64% Today — RQD Quant Desk Flash

$2.52 -10.64% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $2.47

Liminatus Pharma Inc. (Class A) (LIMN) carries a Roarable Rating of D- (Sell) with 35/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • RED ALERT Cap $3.8M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on LIMN Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is LIMN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Liminatus Pharma Inc. (Class A) (NASDAQ: LIMN) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 35/100 at a spot price of $2.52 (-10.64% 1D, market cap $3.8M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 10/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, LIMN ranks #612 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does LIMN compare to CRIS and PMCB in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), LIMN carries a Roarable D- (35/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, CRIS (Curis Inc.) holds a E grade (27/100 RQD, P/E N/A, ROIC -35.0%, cap $4.0M) and PMCB (PharmaCyte Biotech Inc.) posts a E grade (34/100 RQD, P/E N/A, ROIC -30.2%, cap $3.2M). Among the 5-stock peer group, LIMN leads on earnings multiple (N/A) while PMCB leads on capital efficiency (-30.2% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for LIMN?
▼

Per LIMN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001971387), Liminatus Pharma Inc. (Class A) generated $8.3M in revenue (-10.9% YoY), -$10.2M in net income, and -$10.0M in free cash flow against $512.8K in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $2.47 (-2.11%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 7/20 (D-) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (35/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-8.5% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • D-
025507510035
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D
Cash (7)Whales (3)SEC (10)Macro (10)CEO (5)
Each axis scored 0–20
12M PRICE TARGET CONE-10.3% Base Target
$149 Bull$2 Base$2 Bear
📬 FREE LIMN RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for LIMN)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (35/100 Composite)
🔍 WHY LIMN SCORES 35/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (29% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 1/9

▲ #2 Bullish Driver: Macro Regime Fit+10/20 pts (29% of score)

FRED Regime × Technicals: 2% of 52W Range • RSI-14 at 35.6 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
43
Grade D$3.41-5.6% Next Q
Q2 (-2Q)
40
Grade D$3.22-10.2% Next Q
Q3 (-1Q)
38
Grade E$2.89-12.8% Next Q
Current
35
Grade D-$2.52-8.5% Hist 90D α
Trajectory: D (43) → D- (35)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a LIMN Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While LIMN currently carries a cautious 35/100 (D-) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($3.58) and Max Pain ($2.65) forces dealer call-delta covering toward $148.58.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $LIMN• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “LIMN Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 35%NO 65%Trade / Inspect Odds →
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →

Why LIMN Stock dropped -10.64% Today — RQD Quant Desk Flash

Liminatus Pharma Inc. (Class A) (LIMN) dropped -10.64% to $2.52, trading at 2% of its 52-week range ($2.75 – $141.5). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.

  • ▸Technical Tape: Trading at 2% of its 52-week range ($2.75 – $141.5) with RSI-14 at 35.6 (NEUTRAL RANGE).
  • ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $2.52 (no active unusual options sweep snapshot on file).
  • ▸Fundamental Anchor: Roarable D- (Sell) backed by 52% gross margin and $0 annual free cash flow.
Live LIMN Headlines & Catalysts
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring LIMN)

  • ✓Walkthrough of LIMN's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
LIMN // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -76.34%🛡️ HOLDING TREND SUPPORT
2026-11-03O $2.89H $2.89L $2.52C $2.52VOL 13.0K
RES: $6.94SUP: $2.10SMA50: $3.58SMA200: $10.74
$80.35$59.26$38.16$17.07$-4.03RES $6.94SUP $2.10$2.522026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

LIMN Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 LIMN Butterfly Map → + Track LIMN →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. -10.9% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on LIMN today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for LIMN. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for LIMN today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (LIMN)

Health Care Rank #612 of 1015 ⚔️ CRIS vs LIMN Full Matrix →

1. Head-to-Head Health Care Peer Comparison (LIMN vs. CRIS, PMCB, BTTC, CELZ)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Liminatus Pharma Inc. (Class A) (LIMN) ranks #612 by composite RQD confidence (35/100, grade D-) and #959 by equity capitalization ($3.8M). Within this direct 5-issuer industry benchmark cohort, LIMN leads on earnings valuation at N/A trailing P/E, while PMCB leads on capital efficiency and profitability with -30.2% ROIC and — gross margin. BTTC currently holds the highest overall quantitative score in the immediate peer group at 38/100 (D-) compared with LIMN at 35/100 (D-).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
LIMN ACTIVE
Liminatus Pharma Inc. (Class A)
D- 35/100 — — -35.0% -10.64% $3.8M Benchmark Subject
CRIS
Curis Inc.
E 27/100 — — -35.0% +10.17% $4.0M /cris-vs-limn →
PMCB
PharmaCyte Biotech Inc.
E 34/100 — — -30.2% +2.71% $3.2M /pmcb-vs-limn →
BTTC
Black Titan Corporation
D- 38/100 — — — -3.17% $4.8M /bttc-vs-limn →
CELZ
Creative Medical Technology Holdings Inc.
E 20/100 — 63.4% -35.0% -4.81% $5.0M /celz-vs-limn →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2024–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001971387 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Liminatus Pharma Inc. (Class A) (LIMN) reported GAAP revenue of $8.3M (-10.9% vs. FY2024 revenue of $9.3M ) , GAAP net income of -$10.2M, operating cash flow of -$10.0M, and free cash flow of -$10.0M (-587.5% YoY). On the balance sheet, LIMN closed FY2025 with $512.8K in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 1/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $8.3M -$10.2M -$10.0M -$10.0M $512.8K —
FY2024 (FY) 2024-12-31 $9.3M -$3.5M -$1.5M -$1.5M $5.4M —

3. LIMN Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is LIMN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Liminatus Pharma Inc. (Class A) (NASDAQ: LIMN) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 35/100 at a spot price of $2.52 (-10.64% 1D, market cap $3.8M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 10/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, LIMN ranks #612 in composite RQD confidence.

How does LIMN compare to CRIS and PMCB in the Health Care sector?

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), LIMN carries a Roarable D- (35/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, CRIS (Curis Inc.) holds a E grade (27/100 RQD, P/E N/A, ROIC -35.0%, cap $4.0M) and PMCB (PharmaCyte Biotech Inc.) posts a E grade (34/100 RQD, P/E N/A, ROIC -30.2%, cap $3.2M). Among the 5-stock peer group, LIMN leads on earnings multiple (N/A) while PMCB leads on capital efficiency (-30.2% ROIC).

What are the biggest fundamental strengths and SEC risk factors for LIMN?

Per LIMN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001971387), Liminatus Pharma Inc. (Class A) generated $8.3M in revenue (-10.9% YoY), -$10.2M in net income, and -$10.0M in free cash flow against $512.8K in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is LIMN trading relative to its 50-day, 200-day, and 52-week technical levels?

LIMN last traded at $2.52 (-10.64% on volume of 23,977 shares), positioning the stock -29.61% below its 50-day simple moving average ($3.58) and -76.54% below its 200-day simple moving average ($10.74). Across its 52-week range of $2.75 to $141.50, LIMN sits at the 0.0% percentile with a 14-day RSI of 35.6 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($2.20 to $2.84).

Direct Sub-Reports: LIMN RQD Cockpit LIMN 12M Forecast LIMN Earnings & Move LIMN Dividends & DRIP LIMN Insiders & 13F LIMN Whale Options LIMN Profit Sankey LIMN News & Why
ROARABLE RATING BRIEF • RQD 35/100 (D-) ✓ SEC XBRL & RQD VERIFIED

LIMN — Liminatus Pharma Inc. (Class A): What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Liminatus Pharma Inc. (Class A) (LIMN) earns a live Roarable RQD composite score of 35/100, corresponding to a D- letter grade (Roarable Sell) at a spot price of $2.52 (-10.64% 1D, market capitalization $3.8M).

  • Fundamental Cash Engine (7/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of —, and free cash flow yield of —.
  • Whale 13F & Options Flow (3/20) + Insider Conviction (5/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (10/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 1/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Liminatus Pharma Inc. (Class A) (LIMN) is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Biological Products (No Diagnostic Substances) industry..0B. —: specific products, customers, or revenue model descriptions.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Liminatus Pharma Inc. (Class A) (LIMN) reported $8.3M in annual revenue (up from $9.3M in FY2024, -10.9% YoY) and -$10.2M in GAAP net income. Over the multi-year SEC filing window from FY2024 ($9.3M revenue, -$3.5M net income) through FY2025, LIMN scaled operating cash flow to -$10.0M and free cash flow to -$10.0M, backed by $512.8K in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (D- • RQD 35/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 3/20. With Fundamental Cash Engine at 7/20 and Institutional Whale Flow at 3/20, sustained execution supports upside toward the upper end of the $2.75 – $141.50 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

—: upstream suppliers, downstream customers, and sector correlation mappings. Investors should note that the 52-week range and the presence of a warrant-related reference (LIMNW) in the news feed are the only ripple-type observations available, and neither is resolved by the source data.

  • Key Question #1: Can LIMN sustain or expand its — operating margin and -35.0% ROIC against Biotechnology: Biological Products (No Diagnostic Substances) peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $8.3M and free cash flow of -$10.0M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is LIMN's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

LIMN Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Liminatus Pharma Inc. (Class A) (LIMN) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to LIMN Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

LIMN Bull vs. Bear Conversation Board — What's Your Call at $2.52?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON LIMN 🐻 33% BEARISH CONVICTION
1. Pick Your Side on LIMN:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
TA TapeReader_Pro RQD DEBATE OPENER • Price Action & Volume Trader 🐂 BULLISH 🎯 Target: $3.61 (+28.0%)
📌 Pinned Debate

The stock trades at a $3.9M market capitalization, so a meaningful shift in cash generation or sponsorship could move the valuation sha

Picked up a starter position in LIMN in my $100K Virtual Cash book at $2.82. The stock trades at a $3.9M market capitalization, so a meaningful shift in cash generation or sponsorship could move the valuation sharply from its current low base.. Trading inside a $2.75–$141.50 52-week range with 0.0% FCF yield gives solid downside support if Biotechnology: Biological Products (No Diagnostic Substances) multiples expand this quarter.

ArenaChamp_24 🐂 BULL

@TapeReader_Pro Agree on the RQD 35/100 quality, though with 1.0 beta I'm scaling in with half-size at $2.82 and keeping dry powder in case we test $2.62.

SK SkepticalCFA RQD DEBATE OPENER • Fundamental Contrarian 🐻 BEARISH 🎯 Target: $2.37 (-16.0%)
Spot @ $2.82

With ROIC at -35%, FCF yield at 0%, Piotroski F at 1/9, and a 52-week range of $2.75 to $141.5, the data points to ongoing losses and w

Careful chasing LIMN at $2.82. With ROIC at -35%, FCF yield at 0%, Piotroski F at 1/9, and a 52-week range of $2.75 to $141.5, the data points to ongoing losses and weak forensic quality.. Gross margin is 0.0%, but operating margin is 0.0%, which shows SG&A and reinvestment are eating into bottom-line EPS. Target $2.37 on multiple compression.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $202.06 -1.26% AAPL $338.32 -1.83% MSFT $507.12 -2.83% TSLA $403.82 +1.00% PLTR $178.34 -3.13% SOFI $16.60 -0.95% IBIT $43.35 -5.42% GLD $361.65 -3.59%